Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion. The option begins a due diligence period for EHSI and also begins good faith negotiations between both parties with the intention of reaching a potential Sub-License Agreement. Regenevita (www.regenevita.com) is a subsidiary of Stematix, Inc. (www.stematix.com), and is a joint venture between Stematix and EDCO Ventures (www.edcoonline.org) with a goal to establish pioneering leadership in regenerative medicine for the Rio Grande / Rio Bravo Valley. Regenevita believes it has a unique, sustainable cellular banking model that can facilitate the widespread use of regenerative cell therapy.
“Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements.”
"We are very impressed with the leadership and development team of Regenevita. It is our belief they have the ability to emerge as world leaders in the advancement of stem cell technology and research," stated Cindy Morrissey, President of EHSI. "Our participation in this deal has the potential to reap generous rewards for our company in both revenue and technological advancements."